Brief: U.S. Court Of Appeals For The Federal Circuit Affirms Prior Delaware District Court Rulings In Favor Of Acadia In Nuplazid® (Pimavanserin) Composition Of Matter Patent
09/06/2025 21:03
ACADIA Pharmaceuticals Inc ACAD.O: U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT AFFIRMS PRIOR DELAWARE DISTRICT COURT RULINGS IN FAVOR OF ACADIA IN NUPLAZID® (PIMAVANSERIN) COMPOSITION OF MATTER PATENT ACADIA PHARMACEUTICALS INC - NUPLAZID PATENT PROTECTION EXTENDED TO 2030 Source text: ID:nBw1cL5Rza Further company coverage: ACAD.O
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP